---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-005116"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:33:19.926004+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharma reports $280.8M cash; pipeline milestones extend into 2023

## Summary
- Cash, cash equivalents and investments of $280.8M as of Dec 31, 2021; funds operations into first half of 2024.
- ORIC-101 Phase 1b updates from two combination trials expected in first half of 2022.
- Initial Phase 1b data for ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), and ORIC-944 (prostate cancer) expected in first half of 2023.
- Two discovery programs advanced into lead optimization; new program/indication to be announced in 2022.

## SEC filing metadata
- accession: 0001193125-22-005116
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312522005116/0001193125-22-005116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312522005116/d243804d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-005116
- JSON: https://secwatch.observer/filing/0001193125-22-005116.json
- Plain text: https://secwatch.observer/filing/0001193125-22-005116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.